

September 2015 Appendix 4C

Melbourne, Australia, 30 October 2015

Prescient Therapeutics Limited (“**Prescient**” or “**the Company**”) provides the following Appendix 4C in relation to the quarter ended 30 September 2015.

During the quarter, Prescient continued its Phase 1b/2 clinical study of novel cancer drug PTX-200 trial in breast, lung and esophageal cancer. The study is being conducted as an Investigator Sponsored Trial (IST) under the lead of Professor Joseph Sparano, Professor of Medicine & Obstetrics, Gynecology, and Women's Health at Montefiore Medical Center and the Albert Einstein College of Medicine and Cancer Center, and has been partially funded by the U.S. National Cancer Institute.

To date 15 patients with advanced cancer have been treated with Prescient's PTX-200 in combination with weekly paclitaxel chemotherapy in this Phase 1b study with early evidence of antitumor activity noted. PTX-200 inhibits an important tumor survival pathway known as AKT, which plays a key role in the development of many tumors, and contributes to paclitaxel resistance. Dose escalation of PTX-200 has proceeded to the third and final dose level, and the researchers will soon initiate an expansion cohort in 12 patients at the recommended Phase 2 dose of PTX-200 to better characterize the safety profile of the combination.

A previous Phase 1 clinical study using PTX-200 as a single agent carried out at the M.D. Anderson and Moffitt Cancer Centers in patients with advanced leukemia showed stabilization of disease in 17 of 32 patients after a single round of treatment with 3 patients showing a decrease in the number of leukemic blast cells with 1 patient showing a marked reduction in leukocytosis and spleen size.

An additional Phase 1b/2 clinical trial of PTX-200 is underway in patients with recurrent or persistent platinum resistant ovarian cancer at the Moffitt Cancer Centre, and Prescient is planning a Phase 1b/2 trial evaluating PTX-200 in combination with cytarabine in acute leukemia, a follow on from the Phase 1b study that has already completed.

During the quarter, the Company substantially bolstered its intellectual property portfolio with two new US patents granted to protect its lead asset PTX-200.

The first patent, US Patent 9,101,641, covers Prescient's method for treating patients with tumours that overexpress AKT kinase, a key molecule in the oncogenic AKT signaling pathway.

Prescient's lead drug PTX-200 is a novel small molecule that works by blocking the AKT pathway, and inhibiting tumour growth.

High AKT expression is associated with a poor prognosis, resistance to chemotherapy and shortened survival times in a range of cancers. Trials of PTX-200 are currently underway in the United States in patients with breast and ovarian cancers.

Further expanding the company's IP portfolio is granted US Patent No. 9,115,162, which covers a proprietary method for identifying and treating a cancer patient with enhanced sensitivity to PTX-200 through a direct measurement of AKT levels in the patient's tumour. This patent further strengthens Prescient's focus on

“personalised medicine” whereby patients are selected based on their tumour blueprint and treated with a specific drug that targets such blueprint, hence increasing the likelihood that a patient will respond to the drug. Personalized or tailored medicine is the way of the future, breaking the “one size fits all” approach to drug treatment that has seen many failures in the past.

The Company was also pleased to announce that its Chief Scientific Officer and co-inventor of PTX’s technologies, Professor Said Sebti, has been named as one of the Top 20 Translational Researchers in the world by the prestigious science publisher Nature Publishing Group.

Professor Sebti has been ranked alongside Nobel laureate Dr David Baltimore on the internationally regarded list, which is compiled by patent analytics firm IP Checkups following examination of 2014’s most active scientists for patenting

Cash at 30 September 2015

Cash at the end of the quarter, as detailed in the attached Appendix 4C, was approximately \$0.75 million.

Change to principal place of business

Prescient advises that it has now changed its principal place of business to its registered office at Level 4, 100 Albert Road, South Melbourne, Victoria, 3205.

About Prescient Therapeutics

Prescient Therapeutics is a clinical stage oncology company developing novel compounds that show great promise as potential new therapies to treat a range of cancers that have become resistant to front line chemotherapy.

Lead drug candidate PTX-200 inhibits an important tumor survival pathway known as AKT, which plays a key role in the development of many cancers, including breast and ovarian cancer, as well as leukaemia. This highly promising compound is now the focus of two current clinical trials. The first is a Phase 1b/2 study of PTX-200 in breast cancer patients at the prestigious Montefiore Cancer Center in New York. The second is also a Phase 1b/2 trial in patients with recurrent or persistent platinum resistant ovarian cancer at Florida’s Lee Moffitt Cancer Center. In addition, Prescient is planning a Phase 1b/2 trial evaluating PTX-200 as a new therapy for acute myeloid leukemia in 2015.

Prescient’s second novel drug candidate, PTX-100, is a first in class compound with the ability to block important cancer-causing proteins such as Ral and Rho, leading to apoptosis (death) of cancer cells. PTX-100 was well tolerated and achieved stable disease in a Phase 1 trial in advanced solid tumors. Prescient expects to commence Phase 1b/2 clinical trials in breast cancer and multiple myeloma in 2015. At the same time, Prescient plans to develop its novel p27 cancer biomarker as a companion diagnostic that will potentially identify those patients that are most likely to respond to PTX-100 therapy.

Prescient has licensed access to its Co-X-Gene™ platform technology to French biotechnology company Transgene for use in two immunotherapeutic products.

Contact:

Mr Paul Hopper (Executive Director)
Ms Melanie Leydin (Company Secretary)
Ph: +61 (0) 3 9692 7222

Appendix 4C

Quarterly report for entities admitted on the basis of commitments

Introduced 31/3/2000. Amended 30/9/2001, 24/10/2005, 17/12/2010

Name of entity

Prescient Therapeutics Limited
(Formerly Virax Holdings Limited)

ABN

56 006 569 106

Quarter ended ("current quarter")

30 SEPTEMBER 2015

Consolidated statement of cash flows

Cash flows related to operating activities	Current quarter \$A'000	Year to date (3 months) \$A'000
1.1 Receipts from customers	-	-
1.2 Payments for:		
(a) staff costs	(93)	(93)
(b) advertising and marketing	(6)	(6)
(c) research and development	(185)	(185)
(d) leased assets	-	-
(e) other working capital	(183)	(183)
1.3 Dividends received	-	-
1.4 Interest and other items of a similar nature received	-	-
1.5 Interest and other costs of finance paid	-	-
1.6 Income taxes paid	-	-
1.7 Other items		
(a) Net GST (paid to)/recovered from ATO	113	113
(b) R & D tax rebate received	-	-
(c) Government grant received	-	-
(d) R&D contract contributions received	-	-
Net operating cash flows	(354)	(354)

+ See chapter 19 for defined terms.

Appendix 4C
Quarterly report for entities
admitted on the basis of commitments

	Current quarter \$A'000	Year to date (3 months) \$A'000
1.8 Net operating cash flows (carried forward)	(354)	(354)
Cash flows related to investing activities		
1.9 Payment for acquisition of:		
(a) businesses (item 5)	-	-
(b) equity investments	-	-
(c) intellectual property	-	-
(d) physical non-current assets	-	-
(e) other non-current assets	-	-
1.10 Proceeds from disposal of:	-	-
(a) businesses (item 5)	-	-
(b) equity investments	-	-
(c) intellectual property	-	-
(d) physical non-current assets	-	-
(e) other non-current assets	-	-
1.11 Loans to other entities	-	-
1.12 Loans repaid by other entities	-	-
1.13 Other (provide details if material)	-	-
Net investing cash flows	-	-
1.14 Total operating and investing cash flows	(354)	(354)
Cash flows related to financing activities		
1.15 Proceeds from issues of shares, options, etc.	-	-
1.16 Proceeds from sale of forfeited shares	-	-
1.17 Proceeds from borrowings	-	-
1.18 Repayment of borrowings	-	-
1.19 Dividends paid	-	-
1.20 Capital raising costs	-	-
Net financing cash flows	-	-
Net increase (decrease) in cash held	(354)	(354)
1.21 Cash at beginning of quarter/year to date	1,043	1,043
Exchange rate adjustments to item 1.20	66	66
1.23 Cash at end of quarter	755	755

+ See chapter 19 for defined terms.

Payments to directors of the entity and associates of the directors

Payments to related entities of the entity and associates of the related entities

		Current quarter \$A'000
1.24	Aggregate amount of payments to the parties included in item 1.2	81
1.25	Aggregate amount of loans to the parties included in item 1.11	-

1.26 Explanation necessary for an understanding of the transactions

Directors' fees and Executive Directors' salaries paid during the September 2015 quarter.

Non-cash financing and investing activities

2.1 Details of financing and investing transactions which have had a material effect on consolidated assets and liabilities but did not involve cash flows

-

2.2 Details of outlays made by other entities to establish or increase their share in businesses in which the reporting entity has an interest

-

Financing facilities available

Add notes as necessary for an understanding of the position.

		Amount available \$A'000	Amount used \$A'000
3.1	Loan facilities	-	-
3.2	Credit standby arrangements	-	-

+ See chapter 19 for defined terms.

Appendix 4C
Quarterly report for entities
admitted on the basis of commitments

Reconciliation of cash

Reconciliation of cash at the end of the quarter (as shown in the consolidated statement of cash flows) to the related items in the accounts is as follows.		Current quarter \$A'000	Previous quarter \$A'000
4.1	Cash on hand and at bank	735	1,043
4.2	Deposits at call	20	-
4.3	Bank overdraft	-	-
4.4	Other (provide details)	-	-
Total: cash at end of quarter (item 1.23)		755	1,043


Acquisitions and disposals of business entities

	Acquisitions (Item 1.9(a))	Disposals (Item 1.10(a))
5.1	Name of entity	-
5.2	Place of incorporation or registration	-
5.3	Consideration for acquisition or disposal	-
5.4	Total net assets	-
5.5	Nature of business	-

+ See chapter 19 for defined terms.

Compliance statement

- 1 This statement has been prepared under accounting policies which comply with accounting standards as defined in the Corporations Act (except to the extent that information is not required because of note 2) or other standards acceptable to ASX.
- 2 This statement does give a true and fair view of the matters disclosed.

Sign here:  Date: 30 October 2015
(Company Secretary)

Print name: Melanie Leydin

Notes

1. The quarterly report provides a basis for informing the market how the entity's activities have been financed for the past quarter and the effect on its cash position. An entity wanting to disclose additional information is encouraged to do so, in a note or notes attached to this report.
2. The definitions in, and provisions of, *AASB 107: Statement of Cash Flows* apply to this report except for any additional disclosure requirement requested by AASB 107 that are not already itemised in this report.
3. **Accounting Standards.** ASX will accept, for example, the use of International Financial Reporting Standards for foreign entities. If the standards used do not address a topic, the Australian standard on that topic (if any) must be complied with.

+ See chapter 19 for defined terms.